title: Scintigraphic prediction of left ventricular functional recovery early after primary coronary angioplasty using single-injection quantitative electrocardiographic gated SPECT.
abstract: OBJECTIVE
  The clinical usefulness of characterizing reperfused myocardium by perfusion/thickening assessment using electrocardiographic gated single photon emission computed tomography (SPECT) has not been investigated. We evaluated whether single-injection gated SPECT with 99mTc tetrofosmin early after primary percutaneous coronary intervention (PCI) can predict left ventricular (LV) functional recovery.
  
  
  METHODS
  Gated SPECT was performed 3 days after primary PCI in 45 patients with acute myocardial infarction and revascularized segments were classified into perfusion/thickening mismatched segments, matched normal and matched abnormal segments. Gated SPECT was repeated 3 months later to evaluate the changes in LV ejection fraction (deltaLVEF).
  
  
  RESULTS
  Among 332 revascularized segments, there were 83 mismatched segments, 163 matched abnormal segments and 86 matched normal segments. In all the patients, LVEF increased significantly from 3 days to 3 months after primary PCI (52+/-13 to 57+/-14%, P<0.0001). Patients were divided into two groups according to deltaLVEF: 24 patients with LV functional recovery (deltaLVEF > or = 5%) and 21 patients without LV functional recovery. The number of mismatched segments in patients with LV functional recovery was significantly greater than that in patients without (2.7+/-1.7 vs. 0.8+/-1.4, P<0.0003) despite no differences in the number of matched abnormal and matched normal segments. There was a significant correlation between deltaLVEF and the number of mismatched segments (r=0.56, P<0.0001) and LVEF at 3 months after primary PCI was related to the number of matched abnormal segments (r=-0.78, P<0.0001).
  
  
  CONCLUSIONS
  Single-injection gated SPECT early after primary PCI can predict LV functional recovery.
authors.affiliation: Cardiovascular Division, Department of Medicine II, Kansai Medical University, Osaka, Japan.
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Kurihara
authors.forename: Seishi
authors.initials: S
authors.lastname: Nakamura
authors.forename: Kazuya
authors.initials: K
authors.lastname: Takehana
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Fukui
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Sawanishi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Maeba
authors.forename: Takanao
authors.initials: T
authors.lastname: Ueyama
authors.forename: Kengo
authors.initials: K
authors.lastname: Hatada
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sugiura
authors.forename: Toshiji
authors.initials: T
authors.lastname: Iwasaka
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D005260:Female; D015637:Gated Blood-Pool Imaging / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging* / Q000601:surgery*; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D011379:Prognosis; D019275:Radiopharmaceuticals; D020127:Recovery of Function / Q000502:physiology*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013318:Stroke Volume; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000209:etiology / Q000601:surgery*
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin